Thromboxane A2 (TXA2) is a labile metabolite of arachidonic acid that has potent biological effects. Its actions are mediated by G protein-coupled thromboxane-prostanoid (TP) receptors. TP receptors have been implicated in the pathogenesis of cardiovascular diseases. To investigate the physiological functions of TP receptors, we generated TP receptor-deficient mice by gene targeting. Tp-/-animals reproduce and survive in expected numbers, and their major organ systems are normal. Thromboxane agonist binding cannot be detected in tissues from Tp-/-mice. Bleeding times are prolonged in Tp-/-mice and their platelets do not aggregate after exposure to TXA2 agonists. Aggregation responses after collagen stimulation are also delayed, although ADP-stimulated aggregation is normal. Infusion of the TP receptor agonist U-46619 causes transient increases in blood pressure followed by cardiovascular collapse in wild-type mice, but U-46619 caused no hemodynamic effect in Tp-/-mice. Tp-/-mice are also resistant to arachidonic acid-induced shock, although arachidonic acid signifi-cantly reduced blood pressure in Tp-/-mice. In summary, Tp-/-mice have a mild bleeding disorder and altered vascular responses to TXA2 and arachidonic acid. Our studies suggest that most of the recognized functions of TXA2 are mediated by the single known Tp gene locus. 
Introduction
TXA 2 is a biologically active lipid mediator that is produced by the metabolism of arachidonic acid through the cyclooxygenase pathway. In aqueous solutions, TXA 2 is rapidly hydrolyzed to TXB 2 , a stable and inactive metabolite. Because of its short half-life ( Ͻ 30 s), TXA 2 functions primarily as an autocoid and its actions are limited to tissues in proximity to the sources of its synthesis. Previous studies have suggested that TXA 2 contributes to vascular homeostasis through its actions as a potent vasoconstrictor and platelet aggregant (1) (2) (3) . In the kidney, TXA 2 appears to regulate renal hemodynamics and sodium handling (4) (5) (6) (7) (8) . TXA 2 may also play a role in the immune system through effects on thymic cell selection (9) and through direct effects on T cell functions (10, 11) . Finally, dysregulation of TXA 2 synthesis and actions has been implicated in the pathogenesis of a number of disease states including cardiovascular disease (12) , asthma (13) , eclampsia (14, 15) , and a variety of kidney diseases (3, (16) (17) (18) .
The actions of TXA 2 are mediated by cell surface receptors (thromboxane-prostanoid receptors, by convention designated TP) 1 which are members of the G protein-coupled receptor superfamily (19) . TP receptors are expressed in a number of tissues including thymus, platelets, lung, kidney, spleen, and placenta (20, 21) . While the thromboxane receptors that have been cloned to date demonstrate substantial homology (20) (21) (22) , earlier pharmacological studies had suggested heterogeneity of function and agonist binding characteristics (23) (24) (25) (26) (27) . For example, in mesangial cells, vascular smooth muscle cells, and platelets, activation of the thromboxane receptor is associated with rapid increases in intracellular calcium that are dependent on phospholipase C activation (5, 25, 28, 29) , whereas in macrophages the TP receptor may be linked to adenyl cyclase (30) . A structural basis for these differences in second messenger coupling and ligand binding affinities has not been determined clearly. It has been hypothesized that these differences in biochemical properties might be mediated by TP receptor isoforms encoded by distinct genes. However, so far only a single TP receptor gene locus ( Tp ) has been identified (31) .
Experiments defining roles for TXA 2 in physiological processes have relied primarily on pharmacological inhibitors of thromboxane synthase or thromboxane receptor antagonists. These pharmacological approaches have inherent limitations related to the potency, specificity, and dosage of individual agents. To further examine in vivo functions of TP receptors, we used gene targeting to produce TP receptor-deficient mice. Our studies suggest a key role for the TP receptor in hemostasis and regulation of certain vascular responses. In addition, our data are consistent with the existence of only one Tp gene.
Methods

Disruption of the Tp gene in embryonic stem (ES) cells.
To clone the mouse Tp gene, a partial complementary DNA probe was prepared by PCR after reverse transcription of total RNA isolated from mouse lung. The PCR primer sequences were derived from the published sequence of the mouse TP receptor cDNA (21): 5 Ј primer (5 Ј -TCTTG-GTGCTTCCTGACACT-3 Ј ) and 3 Ј -primer (5 Ј -GGAGCTGTGAA-CTGAACCGC-3 Ј ). The resulting 438-bp partial cDNA fragment corresponds to the region of the TP receptor protein extending from the second extracellular loop through the proximal half of the intracellular cytoplasmic tail.
This probe was used to screen a complete BamHI-digested genomic library constructed in the lambda DashII phage vector using genomic DNA isolated from the mouse ES cell line E14tg2a. Hybridizing phages were purified and a restriction map of the genomic DNA fragment was prepared, as depicted in Fig. 1 A . To construct the targeting vector, an 8-kb KpnI fragment containing exons 2 and 3 of the TP receptor and encompassing all of the protein coding sequences was subcloned into pBluescript KS (Stratagene Inc., La Jolla, CA). A neomycin resistance gene driven by the phosphoglycerol kinase (PGK) promoter was inserted into a unique SfiI site near the proximal end of exon 2. This insertion disrupts the coding sequence of the Tp gene in the third transmembrane domain. ES cells were grown, transformed, and screened using standard methodologies (32) . Colonies in which the plasmid had integrated by homologous recombination were identified by Southern analysis using the 3 Ј probe shown in Fig. 1 .
Generation of Tp-deficient mice. Targeted ES cells were introduced into C57BL/6 mouse blastocysts using standard techniques (32) . Male chimeras were mated with B6D2 (C57BL/6 ϫ DBA/2 F 1 ; The Jackson Laboratory, Bar Harbor, ME) or 129/SvEv females to identify germline competent chimeras that were capable of transferring the genetically modified ES cell genome to their offspring. The targeted Tp allele was detected in offspring of these crosses by Southern blot analysis of genomic DNA isolated from tail biopsies as shown in Fig. 1 . Offspring carrying the mutant allele were intercrossed to obtain animals that were homozygous for the targeted mutation ( Tp
RNA isolation and Northern analysis. Thymuses were harvested from Tp
ϩ / ϩ and Tp Ϫ / Ϫ mice and RNA was extracted from the tissues using a commercially available reagent (Tri-reagent; Sigma Chemical Co., St. Louis, MO). 15 g of total RNA per sample was denatured and size-fractionated in glyoxal-dimethyl sulfoxide gels and transferred to nylon membranes (33) . The 438-bp mouse Tp partial cDNA fragment that had been generated by RT-PCR (see above) was subcloned into pBluescript KS (Stratagene, La Jolla, CA) and sequenced to determine its orientation. The plasmid was then linearized and used to generate an antisense 32 P-CTP labeled riboprobe (MAXIscript; Ambion, Inc., Austin, TX). The membranes were hybridized at high stringency and after washing, the filters were exposed to Kodak X-AR film for up to 1 wk at Ϫ 80 Њ C.
TP receptor ligand-binding studies. TXA 2 receptor in thymocytes was detected using an 125 I-labeled thromboxane receptor agonist IBOP (a gift from Perry Haluska) (34) [1S-(1 alpha,2 beta(5Z),3 alpha-(1E,3S)4 alpha)-7-(3-(3-hydroxy-4-(p-iodophenoxy)-1-butenyl)-7-oxabicyclo(2.2.1)hept-2-yl)-5-heptenoic acid]. Thymocyte suspensions were prepared from Tp ϩ / ϩ ( n ϭ 5) and Tp Ϫ / Ϫ ( n ϭ 6) mice by gently grinding the thymus between glass slides. The cells were washed once in PBS and then resuspended in ice-cold PBS containing 10 mM Tris HCl (pH 7.4), 1% BSA, and 10 M indomethacin. Aliquots of 10 6 thymocytes in triplicate were incubated with 100 pM 125 I-BOP for 30 min at 37 Њ C with or without excess concentrations (2 M) of unlabeled IBOP. The incubation mixtures were filtered through Whatman GF/C glass fiber filters and the filters were washed twice with 3 ml ice-cold incubation buffer.
125
I counts were determined using a gamma counter. Specific binding was calculated as the total binding minus background and binding was expressed as a percentage of the total counts that were initially added to the cells (percent specific counts).
TP receptor autoradiography. TXA 2 binding in kidney sections was determined using 125 I-BOP as described previously (27) . After anesthesia with isofluorane, kidneys were removed from Tp ϩ / ϩ and Tp Ϫ / Ϫ mice, the capsule was excised, the tissue was embedded in O.T.C. compound (Miles, Elkhart, IN), and frozen in liquid nitrogenchilled isopentane. Tissue blocks were sectioned serially (20 m) on a cryostat and thaw-mounted on glass microscope slides (FisherPlus; Fisher Scientific, Pittsburgh, PA). The mounted tissue sections were first preincubated in Dulbecco's PBS, pH 6.5, with 10 mM Tris-HCl, 2% BSA, and 10 M indomethacin for 10 min at 25 Њ C. The buffer was replaced with 200 pM 125 I-BOP in 10 mM PBS containing 150 mM NaCl, 5 mM EDTA, 0.3 mM bacitracin, 2% BSA, and 10 M indomethacin. Excess concentrations (10 M) of unlabeled IBOP were added to some sections to define nonspecific binding. After incubation for 1 h in high humidity at 25 Њ C, the radioligand binding mixture was aspirated, and slide-mounted tissues were washed four times for 10 min each with ice-cold Dulbecco's PBS, pH 6.5, containing 10 mM Tris-HCl and 0.5% BSA and rinsed twice with ice-cold distilled water. The slides were dried, desiccated overnight at 25 Њ C, and then exposed to high-resolution x-ray film (Hyperfilm-betamax; Amersham International plc, Little Chalfont, Buckinghamshire, UK) for up to 1 wk. Prints were made from the tissue autoradiograms using F5 Kodabromide paper (Eastman Kodak, Rochester, NY).
Cytofluorometry. Flow cytometry on splenocytes and thymocytes was performed as described previously (35) . In brief, spleen and thymus were isolated from Tp ϩ / ϩ and Tp Ϫ / Ϫ mice and cell suspensions were obtained by gently grinding the tissue between sterile glass slides. Cells were resuspended (2 ϫ 10 6 cells/ml) in cold buffer (PBS/ 2% FBS/0.05% NaN 3 ). 100-l aliquots of resuspended cells were incubated with optimal concentrations of antibody for 30 min at 4 Њ C, and were washed three times in buffer. The mAbs used were: GK 1.5 (anti-CD4), 53-6.7 (anti-CD8), 30-H122 (anti-Thy 1.2) RA36B2 (anti-B220), and M1/70 (anti-CD11b) (all from PharMingen, San Diego, CA). An irrelevant isotypic antibody R35-95 (rat IgG2a; PharMingen) was used as a control for nonspecific staining. After final washing, cells were fixed with PBS containing 2% formalin and were analyzed within 72 h. Analyses and sorting were performed in a FACScan ® (Becton Dickinson, Mountain View, CA). Forward scatter threshold was set to exclude dead cells and debris from acquisi- Bleeding time measurement. Bleeding times were assessed in conscious mice as described by Dejana et al. (36) . The mice were placed into a restraining device and their tails were secured in a vertical position throughout the test. An ‫ف‬ 3-5-mm segment of the tail was transected using a disposable scalpel, and the remaining length of tail was immersed immediately into 37ЊC sterile isotonic saline. Bleeding time was calculated from the time of tail transection until visible bleeding could no longer be detected. If active bleeding continued for Ͼ 10 min, the experiment was terminated and the bleeding site was cauterized.
Platelet aggregation assays. After anesthesia with isofluorane, ‫ف‬ 1 ml of whole blood was removed by cardiac puncture into 10 U of heparin. The heparinized blood was centrifuged at 100 g for 10 min at room temperature and the platelet-rich plasma (PRP) was removed. The remaining fractions were centrifuged at 2,400 g and the supernatant of platelet-poor plasma (PPP) was reserved. The number of platelets in the PRP was determined using a hemacytometer and the volume was adjusted with PPP to achieve a concentration of 3 ϫ 10 5 platelets/l. Platelet aggregation was determined by light absorbance using a platelet aggregation profiler (model PAP-4; Bio/Data Corp., Horsham, PA). The baseline was set using PPP, and aggregation of individual PRP samples was determined after the addition of a series of compounds. Agents that were used to induce platelet aggregation included: 20 M U-46619; (15S)-hydroxy-11,9-(epoxymethano)prosta-5Z,13E-dienoic acid, a thromboxane receptor agonist (Cayman Chemical Co., Ann Arbor, MI); 4 M ADP (Sigma Chemical Co., St. Louis, MO); and collagen reagent 0.05 mg/ml (Sigma Chemical Co.). After addition of agonist, platelet aggregation was monitored for 5-8 min.
Systolic blood pressure measurements in conscious mice. Systolic blood pressures were measured in conscious mice using a computerized tail cuff system (Visitech Systems, Cary, NC) that determines systolic blood pressure using a photoelectric sensor (37) . This system allows pressures to be measured in four mice simultaneously and minimizes the potential for observer bias. Before the study was initiated, mice were adapted to the apparatus for at least 5 d. The validity of this system has been established previously (37) and we have demonstrated its correlation with intraarterial pressure measurements in several experimental systems (38, 39) .
Intraarterial blood pressure measurements and assessment of vascular responses to infusion with the TP receptor agonist U-46619 or arachidonic acid. Tp
ϩ/ϩ and Tp Ϫ/Ϫ mice were anesthetized with isofluorane, a short length of polyethylene (PE-50) tubing was placed in the trachea to facilitate spontaneous ventilation, a flexible plastic catheter (Micro Renathane, type MRE-040, 0.040 O.D. ϫ 0.025 I.D.; Braintree Scientific Co., Braintree, MA) was placed in the carotid artery to monitor arterial pressure, and a second catheter was placed in the jugular vein to infuse vasoactive compounds. Intraarterial blood pressure was recorded continuously through the carotid catheter using Windaq data acquisition and playback software (Dataq Instruments, Akron, OH) as described previously (39, 40) .
After the surgical preparation was completed, the effects of intravenous infusions of vasoactive compounds on mean arterial pressure (MAP) were determined as described previously (39, 40) . Beginning with an equilibration period of 5-10 min, blood pressure was recorded continuously for the duration of each experiment at 50 recordings/s. To facilitate their analysis, the data collected from each animal were compressed to 5 readings/s and the MAP tracings from animals in each experimental group were integrated and averaged. Immediately after the equilibration period, the mice first received a bolus injection of 0.9% sodium chloride solution in a volume (1 l/g body wt) that was identical to the subsequent injections. In separate experiments, mice received either a single 10 mg/kg bolus of arachidonic acid (Cayman Chemical Co.) or two consecutive bolus infusions of U-46619 (100 g/kg and 1 mg/kg; Cayman Chemical Co.) separated by 5 min.
Data analysis. The values for each parameter within a group are expressed as the meanϮSEM. For comparisons between Tp ϩ/ϩ and Tp Ϫ/Ϫ groups, statistical significance was assessed using an unpaired t test. A paired t test was used for comparisons within groups.
Results
Generation of Tp-deficient mice. The gene encoding the TP receptor was disrupted in the E14Tg2a ES cell line by homologous recombination with the targeting plasmid shown in Fig. 1 . Sequence analysis of our genomic clone suggested that the organization of the mouse Tp gene is similar to that described for the human gene (31) wherein exons 2 and 3 contain the entire protein coding region. The targeting plasmid was designed to disrupt the Tp gene by introducing a neomycin resistance cassette into the coding regions of exon 2. Targeted ES cell lines were identified by Southern analysis and introduced into blastocysts to generate chimeric mice. Chimeras were bred to 129/ SvEv or B6/D2 mice and Tp ϩրϪ offspring carrying the mutant allele were identified by Southern analysis as shown in Fig. 1 , C and D.
Mice that were homozygous for the targeted mutation (Tp . The number of Tp Ϫ/Ϫ animals corresponded to that expected (25%) for simple Mendelian inheritance, suggesting that the absence of the TP receptors does not adversely affect intrauterine development or perinatal survival. Furthermore, the Tp Ϫ/Ϫ animals could not be distinguished from normal littermates by simple observation. Histological examination of heart, thymus, spleen, small intestine, lymph nodes, and aorta from the Tp Ϫ/Ϫ animals did not reveal any pathological changes. Since the TP receptor is highly expressed in placenta (20) and uterus (21) , the fertility of Tp Ϫ/Ϫ females was also examined. The frequency of productive matings, gestation, delivery, and care of litters were not different between Tp ϩ/ϩ and Tp Ϫ/Ϫ females. TP receptor mRNA expression in mutant mice. To verify that the targeted mutation introduced into the Tp gene locus resulted in inactivation of the gene, we examined expression of the TP receptor mRNA in thymus by Northern blot, because thymus is the tissue with the highest level of the TP receptor expression. Total RNA was prepared from the thymus of Tp ϩրϩ and Tp Ϫ/Ϫ animals and Northern blot analysis was performed using an antisense riboprobe synthesized from a TP receptor cDNA template. As shown in Fig. 2 , two major bands that hybridized with the Tp probe were detected in RNA prepared from the thymus of wild-type Tp ϩ/ϩ mice including the 2-kb band corresponds to the size of the mouse TP receptor mRNA (21) . Although several aberrant transcripts were observed in Tp ϪրϪ animals, the 2-kb transcript was not detected. TXA 2 radioligand binding studies in thymocytes from Tp mutant mice. To verify that the absence of normal TP receptor mRNA transcripts in Tp Ϫ/Ϫ mice was associated with the loss of functional receptors for TXA 2 , we examined thromboxane binding in thymocytes using the TP receptor agonist IBOP. As shown in Table I 
TP receptor autoradiography in kidney.
In previous studies, we used receptor autoradiography to visualize the distribution and characteristics of thromboxane binding sites in mouse kidney (27) . To define the effect of the TP receptor mutation on renal binding, we performed receptor autoradiography in Tp ϩ/ϩ and Tp Ϫ/Ϫ mice using the TP receptor agonist (Fig. 3 A) . In contrast, no 125 I-BOP binding could be detected in kidney sections from Tp Ϫ/Ϫ mice (Fig. 3 C) . Bleeding time assessment in Tp-deficient mice. TXA 2 is a potent stimulator of platelet aggregation in vitro (41) and naturally occurring mutations of the Tp gene cause abnormal bleeding in humans (42) . Therefore, we determined bleeding times in Tp Ϫ/Ϫ mice. As shown in Table I , bleeding times averaged 96Ϯ5 s in conscious, wild-type mice (n ϭ 11). However, in the Tp Ϫ/Ϫ mice, bleeding times were markedly prolonged (P Ͻ 0.0001 vs. wild-type); all of the Tp-deficient mice continued to bleed for the entire 10-min observation period (n ϭ 6). Because pharmacological antagonism of the TP receptor has only minimal effects on bleeding time in humans, we also measured bleeding time in wild-type mice (n ϭ 6) that had been pretreated with an intravenous infusion of 10 mg/kg of the TP receptor antagonist SQ-29,548. Bleeding times were similarly prolonged (Ͼ 10 min in all animals) in these wild-type mice in which TP receptors were blocked pharmacologically (43) .
Platelet aggregation responses in Tp Ϫ/Ϫ mice. To examine platelet function in Tp Ϫ/Ϫ mice, we performed a series of platelet aggregation studies. As depicted in Fig. 4 , the thromboxane agonist U-46619 induced vigorous aggregation of platelets in wild-type mice (81Ϯ5% aggregation) but caused no detectable aggregation of platelets from Tp Ϫ/Ϫ mice (3Ϯ1% aggregation, P Ͻ 0.0001 vs. wild-type). We also tested whether the absence of TP receptors affected responses to the other platelet ago- nists. After collagen treatment, the delay period (79Ϯ7 s) before platelet aggregation occurred was significantly longer in Tp Ϫ/Ϫ PRP compared with controls (50Ϯ5 s, P ϭ 0.0047 vs. Tp Ϫ/Ϫ PRP). However, the maximum aggregation was similar between the two groups. There was no difference in platelet aggregation responses induced by addition of ADP to PRP from Tp ϩ/ϩ or Tp Ϫ/Ϫ mice.
Systolic blood pressure in Tp
Ϫ/Ϫ mice. Previous studies have suggested a role for the TP receptors in the regulation of blood pressure and hemodynamic responses in various models of hypertension, vascular disease, and shock (44) . To determine whether the absence of TP receptors affected blood pressure homeostasis, we measured systolic blood pressure in conscious mice using an automated tail cuff system as described previously (37) . Systolic blood pressure tended to be lower in the Tp Ϫ/Ϫ mice (114Ϯ3 mmHg) than controls (121Ϯ5 mmHg), but this difference was not statistically significant. Similarly, MAP was not different in anesthetized Tp ϩ/ϩ (93Ϯ4 mmHg) and Tp Ϫ/Ϫ (100Ϯ4) mice. Cardiovascular responses to infusions of a thromboxane receptor agonist or arachidonic acid. Intravenous administration of either TP receptor agonist or arachidonic acid causes a syndrome of cardiovascular collapse and sudden death associated with systemic platelet aggregation, pulmonary thrombosis, and coronary spasm (45) . To determine the effects of the Tp mutation on these responses, we first infused successive boluses of 100 g/kg and 1 mg/kg U-46619 intravenously into anesthetized Tp Ϫ/Ϫ and wild-type mice while simultaneously monitoring MAP. As can be seen in Fig. 5 , the low dose of U-46619 (0.1 mg/kg) caused a transient rise in blood pressure in wildtype animals. The maximal increase of 21Ϯ2 mmHg occurred 60 s after U-46619 infusion and MAP returned to baseline levels after 120 s. The higher dose of thromboxane agonist also caused a transient, early increase in MAP in Tp ϩ/ϩ mice. However, 2-3 min after administration of 1 mg/kg U-46619, MAP began to drop precipitously in the wild-type animals. This was followed by rapid hemodynamic collapse. After receiving the highest dose of U-46619, none of the three Tp ϩ/ϩ animals survived beyond 6 min. In contrast, as shown in Fig. 5 , U-46619 had no detectable effect on MAP in the Tp Ϫ/Ϫ mice. All four Tp Ϫ/Ϫ mice survived to the end of the experiment. The Tp mutation also caused a substantial alteration in the hemodynamic responses to arachidonic acid. As depicted in Fig. 6 , MAP began to fall in the wild-type animals within 120 s after infusion of arachidonic acid. Cardiovascular collapse and shock rapidly ensued. None of the five Tp ϩ/ϩ animals survived beyond 300 s after infusion of the arachidonic acid. As illustrated in Fig. 6 , arachidonic acid also caused a significant lowering of MAP in the Tp Ϫ/Ϫ mice. However, while MAP fell by ‫ف‬ 25 mmHg in Tp Ϫ/Ϫ mice, the animals remained stable at this reduced level of MAP through the remainder of the experiment. All five Tp Ϫ/Ϫ animals survived to the end of the experiment.
Discussion
To assess the role of the thromboxane receptor in development and in the regulation of physiological functions, we used gene targeting to disrupt the Tp locus. Tp null mutant mice are born in the expected Mendelian ratios and appear normal and healthy, suggesting that the TP receptor does not have a unique role in development or in promoting perinatal survival. TP receptors are expressed at high levels in the placenta and uterus and it has been suggested that these receptors may play a functional role in pregnancy, gestation, or delivery. However, we found that Tp Ϫ/Ϫ females have normal frequency of productive matings, viable, normal size litters, and provide normal care for their offspring. Thus, if the TP receptor is involved in perinatal processes, it is not indispensable.
One of the tissues with the highest level of TP receptor expression is the thymus (21) . Within the thymus, the TP receptor is expressed most highly by immature thymocytes. Exposure of these cells to TXA 2 agonists causes apoptosis, suggesting that TXA 2 may play a role in thymic selection (9) . Based on these data, we performed careful analysis of thymic architecture and cellular composition. Although TP receptor ) staining thymocytes within the thymic cortex and medulla, respectively. When thymocytes from wild-type and Tp Ϫ/Ϫ mice were analyzed by flow cytometry, we found no significant differences in their composition or expression of major cell surface markers. These data suggest that absence of the TP receptors from thymus does not substantially alter its structure or cellular composition.
Previously, we used receptor autoradiography to map TXA 2 binding sites within the adult mouse kidney and found significant numbers of binding sites in both the renal cortex and medulla (27) . Analysis of ligand displacement kinetics revealed distinct high-affinity binding sites in the cortex and a predominance of low-affinity sites in the renal medulla. Although the human TP gene encodes two isoforms of the TP receptor (46), we could not detect alternative splicing of the TP receptor mRNA using RT-PCR. To assess whether there might be multiple TP receptor isoforms encoded by additional genes, we performed receptor autoradiography on Tp ϩ/ϩ and Tp Ϫ/Ϫ mice using the TP receptor agonist 125 I-BOP. Neither cortical nor medullary binding was detected in Tp Ϫ/Ϫ mouse kidney. This suggests that all of these binding sites arise from the single known Tp gene locus. Thus, we conclude that if TP receptors in the kidney exist in varying affinity states, they are still products of a single gene.
TP receptors are also expressed at high levels in platelets. Stimulation of this receptor causes TXA 2 synthesis, and platelet activation and aggregation (47) . The marked prolongation of bleeding time in Tp Ϫ/Ϫ mice confirms the importance of this pathway in promoting hemostasis. To determine whether the bleeding defect in Tp Ϫ/Ϫ mice is associated with alterations in platelet function, we examined platelet aggregation responses in TP receptor-deficient mice. In wild-type mice, the TP receptor agonist U-46619 causes rapid, irreversible platelet aggregation. In contrast, platelets from Tp-deficient mice are unresponsive to TP receptor agonist treatment. Thus, disruption of the known Tp gene locus completely eliminates TXA 2 -mediated platelet aggregation.
TXA 2 may have diverse effects on platelet activation and aggregation including direct effects of TXA 2 binding to the platelet TP receptor described above. Alternatively, TXA 2 may promote platelet aggregation by amplifying activation signals of less potent agonists (48) . To examine the contribution of TP receptors to other pathways for platelet activation, we assessed aggregation of Tp Ϫ/Ϫ PRP in response to ADP and collagen. Unlike TXA 2 , ADP causes a reversible aggregation profile in mice but does not trigger the platelet release reaction (49) . When PRP from wild-type or Tp Ϫ/Ϫ mice was exposed to ADP, there was no significant difference in the platelet aggregation responses. These results demonstrate that the TP receptor does not play a significant role in ADPinduced platelet aggregation in mice. This differs from human platelets where ADP causes a reversible aggregation followed by a secondary wave of irreversible aggregation that is dependent on TXA 2 (50) .
Platelets bind to collagen via the cell surface GpIa-IIa receptor (␣2␤1 integrin) (51, 52) , and this binding triggers the activation of a series of several secondary messenger systems and results in platelet aggregation (47) . A role for the TP receptor in this process is confirmed by our observation that the interval between collagen exposure and the onset of platelet aggregation was prolonged in TP receptor-deficient platelets compared with controls. Previous studies had suggested that GpIa-IIa receptor stimulation activates phospholipase A 2 which generates TXA 2 augmenting the activation signals from other second messenger systems (47, 51, 53) . Since the maximal aggregation response was similar between wild-type and Tp Ϫ/Ϫ mice, other activation signals can eventually induce platelet aggregation in the absence of TP receptors. Furthermore, the preserved maximal responses of TP receptor-deficient PRP to ADP and collagen treatment may explain the lack of significant bleeding in Tp Ϫ/Ϫ mice during procedures such as tail biopsy or catheter placement. Intravenous administration of the TXA 2 mimetic U-46619 induces a shock syndrome characterized by cardiovascular collapse and sudden death. This syndrome is associated with systemic platelet aggregation, pulmonary thrombosis, and coronary spasm (45, 54, 55) and suggests a role for TXA 2 septic shock. To determine the role of the Tp gene locus in mediating these effects, we monitored the hemodynamic effect of U-46619 infusion in Tp Ϫ/Ϫ and wild-type mice (Fig. 5) . In Tp ϩ/ϩ mice, the lowest dose of this TP receptor agonist caused transient vasoconstriction whereas the higher dose induced rapid cardiovascular collapse. In contrast, infusion of U-46619 had no detectable effect on systemic hemodynamics in Tp Ϫ/Ϫ mice, suggesting that these actions are mediated exclusively by TP receptors.
Infusion of arachidonic acid also causes shock and sudden death (43, (56) (57) (58) . Similar to the effects of U-46619, Tp Ϫ/Ϫ mice are resistant to hemodynamic collapse induced by arachidonic acid, demonstrating that the effects of arachidonic acid infusion to induce sudden death are mediated primarily by TP receptors. Unlike U-46619, which had no detectable effect on Tp Ϫ/Ϫ mice, infusion of arachidonic acid significantly lowered MAP in Tp Ϫ/Ϫ mice. Although the mechanism of this effect is not clear from our studies, we suggest that this effect may be caused by enhanced production of vasodilatory eicosanoids such as prostaglandin E 2 and prostaglandin I 2 (prostacyclin), which are produced from arachidonic acid substrate.
In summary, these studies have identified a critical role for the Tp gene locus in hemostasis and in mediating vascular responses to arachidonic acid and TXA 2 agonists. The absence of functional TP receptors has no effect on normal development or survival. Our studies provide strong evidence that most of the known functions of TXA 2 can be accounted for by the single known Tp gene locus. These Tp Ϫ/Ϫ mice will be valuable tools for assessing the role of TP receptors in disease states.
